Management of liver transplant recipients with recurrent hepatitis C

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Hepatitis C virus infection is the leading indication for liver transplantation, with recurrent hepatitis C almost universal. Although posttransplant treatment of hepatitis C virus infection remains suboptimal, active investigation continues to inform patient selection and risk-benefit analysis. RECENT FINDINGS: Several key studies have identified components in the immunological response that are associated with the necroinflammatory and fibrotic response. Hepatitis C virus infection is associated with a higher rate of diabetes mellitus after transplant. Patients with diabetes and metabolic syndrome have poorer outcomes, and aggressive management is necessary. Differentiation of acute rejection from recurrent hepatitis C is difficult; however, the use of hepatitis C virus RNA tissue levels, immunohistochemistry and Councilman body/portal tract ratio may help with this diagnostic dilemma. The use of a specific calcineurin inhibitor appears not to influence recurrent hepatitis C, but rapid steroid taper is detrimental and, if steroids are used, long slow taper should be used. Use of rapid and early virological responses is very helpful in the management of hepatitis C after transplantation. In the patients with sustained virological response, histological and survival benefits are noted. SUMMARY: The present review highlights advances in our understanding of the pathophysiology and treatment of hepatitis C virus infection after liver transplantation in the last few years.

Original languageEnglish (US)
Pages (from-to)221-224
Number of pages4
JournalCurrent opinion in organ transplantation
Volume14
Issue number3
DOIs
StatePublished - Jun 1 2009

Fingerprint

Hepatitis C
Hepacivirus
Virus Diseases
Liver
Liver Transplantation
Steroids
Patient Selection
Diabetes Mellitus
Transplantation
Immunohistochemistry
Transplant Recipients
RNA
Transplants
Survival
Therapeutics

Keywords

  • Hepatitis C
  • Histology
  • Immunosuppression
  • Liver transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Management of liver transplant recipients with recurrent hepatitis C. / McCashland, Timothy M.

In: Current opinion in organ transplantation, Vol. 14, No. 3, 01.06.2009, p. 221-224.

Research output: Contribution to journalReview article

@article{2fef4776fad34fe3b62f8df14be00733,
title = "Management of liver transplant recipients with recurrent hepatitis C",
abstract = "PURPOSE OF REVIEW: Hepatitis C virus infection is the leading indication for liver transplantation, with recurrent hepatitis C almost universal. Although posttransplant treatment of hepatitis C virus infection remains suboptimal, active investigation continues to inform patient selection and risk-benefit analysis. RECENT FINDINGS: Several key studies have identified components in the immunological response that are associated with the necroinflammatory and fibrotic response. Hepatitis C virus infection is associated with a higher rate of diabetes mellitus after transplant. Patients with diabetes and metabolic syndrome have poorer outcomes, and aggressive management is necessary. Differentiation of acute rejection from recurrent hepatitis C is difficult; however, the use of hepatitis C virus RNA tissue levels, immunohistochemistry and Councilman body/portal tract ratio may help with this diagnostic dilemma. The use of a specific calcineurin inhibitor appears not to influence recurrent hepatitis C, but rapid steroid taper is detrimental and, if steroids are used, long slow taper should be used. Use of rapid and early virological responses is very helpful in the management of hepatitis C after transplantation. In the patients with sustained virological response, histological and survival benefits are noted. SUMMARY: The present review highlights advances in our understanding of the pathophysiology and treatment of hepatitis C virus infection after liver transplantation in the last few years.",
keywords = "Hepatitis C, Histology, Immunosuppression, Liver transplantation",
author = "McCashland, {Timothy M}",
year = "2009",
month = "6",
day = "1",
doi = "10.1097/MOT.0b013e32832ade76",
language = "English (US)",
volume = "14",
pages = "221--224",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Management of liver transplant recipients with recurrent hepatitis C

AU - McCashland, Timothy M

PY - 2009/6/1

Y1 - 2009/6/1

N2 - PURPOSE OF REVIEW: Hepatitis C virus infection is the leading indication for liver transplantation, with recurrent hepatitis C almost universal. Although posttransplant treatment of hepatitis C virus infection remains suboptimal, active investigation continues to inform patient selection and risk-benefit analysis. RECENT FINDINGS: Several key studies have identified components in the immunological response that are associated with the necroinflammatory and fibrotic response. Hepatitis C virus infection is associated with a higher rate of diabetes mellitus after transplant. Patients with diabetes and metabolic syndrome have poorer outcomes, and aggressive management is necessary. Differentiation of acute rejection from recurrent hepatitis C is difficult; however, the use of hepatitis C virus RNA tissue levels, immunohistochemistry and Councilman body/portal tract ratio may help with this diagnostic dilemma. The use of a specific calcineurin inhibitor appears not to influence recurrent hepatitis C, but rapid steroid taper is detrimental and, if steroids are used, long slow taper should be used. Use of rapid and early virological responses is very helpful in the management of hepatitis C after transplantation. In the patients with sustained virological response, histological and survival benefits are noted. SUMMARY: The present review highlights advances in our understanding of the pathophysiology and treatment of hepatitis C virus infection after liver transplantation in the last few years.

AB - PURPOSE OF REVIEW: Hepatitis C virus infection is the leading indication for liver transplantation, with recurrent hepatitis C almost universal. Although posttransplant treatment of hepatitis C virus infection remains suboptimal, active investigation continues to inform patient selection and risk-benefit analysis. RECENT FINDINGS: Several key studies have identified components in the immunological response that are associated with the necroinflammatory and fibrotic response. Hepatitis C virus infection is associated with a higher rate of diabetes mellitus after transplant. Patients with diabetes and metabolic syndrome have poorer outcomes, and aggressive management is necessary. Differentiation of acute rejection from recurrent hepatitis C is difficult; however, the use of hepatitis C virus RNA tissue levels, immunohistochemistry and Councilman body/portal tract ratio may help with this diagnostic dilemma. The use of a specific calcineurin inhibitor appears not to influence recurrent hepatitis C, but rapid steroid taper is detrimental and, if steroids are used, long slow taper should be used. Use of rapid and early virological responses is very helpful in the management of hepatitis C after transplantation. In the patients with sustained virological response, histological and survival benefits are noted. SUMMARY: The present review highlights advances in our understanding of the pathophysiology and treatment of hepatitis C virus infection after liver transplantation in the last few years.

KW - Hepatitis C

KW - Histology

KW - Immunosuppression

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=67651050045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651050045&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e32832ade76

DO - 10.1097/MOT.0b013e32832ade76

M3 - Review article

C2 - 19444107

AN - SCOPUS:67651050045

VL - 14

SP - 221

EP - 224

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 3

ER -